Rechercher des projets européens

17 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Aggression subtyping for improved insight and treatment innovation in psychiatric disorders (AGGRESSOTYPE)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Aggression is a basic physiological trait with important roles throughout evolution, both in defence and predation. When expressed in humans in the wrong context, aggression leads to maladjustment, social impairment and crime. Despite this, knowledge about aggression aetiology is limited and current treatment strategies are insufficient. Contingent to a subdivision into impulsive and instrumental ...
Voir le projet

 27

 TERMINÉ 

European Medical Information Framework (EMIF)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet

 64

 TERMINÉ 

"Training in neurodegeneration, therapeutics intervention and neurorepair" (TINTIN)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

"Dopamine neurons play a central role in major illnesses, such as anxiety and mood disorders, schizophrenia, autism-spectrum disorders, Parkinson’s disease, epilepsy, and dementia. A multidisciplinary approach must be taken by European researchers to discover the molecular basis of dopamine neurodegeneration and how new technologies will lead to repair and regeneration of neuronal systems in the b ...
Voir le projet

 8

 TERMINÉ 

Multivessel versus culprit lesion only percutaneous revascularization in patients with acute myocardial infarction complicated by cardiogenic shock (CULPRIT-SHOCK)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) represents a major European health care concern with mortality rates between 40-70%. Approximately 70-80% of these patients present with multivessel disease defined as coronary lesions in more than one vessel. The clinician is faced with the decision to either 1) intervene only on the culprit lesion acutely responsible for the i ...
Voir le projet

 23

 TERMINÉ 

Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes (TACTICS)

Date du début: 1 janv. 2012, Date de fin: 30 juin 2017,

Compulsivity is characterized by a repetitive, irresistible urge to perform a behavior, the experience of loss of voluntary control over this intense urge, the diminished ability to delay or inhibit thoughts or behaviors, and the tendency to perform repetitive acts in a habitual or stereotyped manner. Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders t ...
Voir le projet

 13

 TERMINÉ 

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,

Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Voir le projet

 29

 TERMINÉ 

OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) (OPTiMiSE)

Date du début: 1 févr. 2010, Date de fin: 31 juil. 2016,

OPTiMiSE (OPtimization of Treatment and Management of Schizophrenia in Europe) will focus on two goals: optimising current treatments in Schizophrenia and explore novel therapeutic options for schizophrenia. The project intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new and experimental interventions. It is expected that the project wi ...
Voir le projet

 25

 TERMINÉ 

Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% children in Europe. Methylphenidate (MPH) is the most-commonly prescribed medication for ADHD children; it is also increasingly used in ADHD adults. In 2007, the European Commission requested a referral to the Committee for Medicinal Products for Human Use ...
Voir le projet

 17

 TERMINÉ 

Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia (CRESTAR)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses, affecting about 1/3 of patients (~1 million Europeans), a considerable economic and social burden. First-line treatments include atypical (e.g. olanzapine) and typical (e.g. haloperidol) antipsychotics. The original atypical, clozapine, is a final option, and although it is the only antipsychotic shown to b ...
Voir le projet

 11

 TERMINÉ 

European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI)

Date du début: 1 mai 2010, Date de fin: 30 avr. 2015,

The aim of EU-GEI is to identify the interactive genetic, clinical and environmental determinants involved in the development, severity and outcome of schizophrenia (EU-GEI, Schiz. Res. 2008; 102: 21-6). In order to identify these interactive determinants, EU-GEI will employ family-based, multidisciplinary research paradigms, which allow for the efficient assessment of gene-environment interaction ...
Voir le projet

 27

 TERMINÉ 

A Roadmap for Mental Health Research in Europe (ROAMER)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2015,

"On the regional level, Europe has one of the highest levels of resources for mental health care. Despite this, the high burden and impact of mental disorders in Europe is expected to rise. “ROAdmap for Mental health Research” (ROAMER) is designed to develop a comprehensive, consensus-based roadmap to promote and integrate mental health and well-beingresearch in Europe. Research advances and innov ...
Voir le projet

 15

 TERMINÉ 

THERAPEUTIC AND PREVENTIVE IMPACT OF NUTRITIONAL LIPIDS ON NEURONAL AND COGNITIVE PERFORMANCE IN AGING, ALZHEIMER’S DISEASE AND VASCULAR DEMENTIA (LIPIDIDIET)

Date du début: 1 août 2008, Date de fin: 31 mars 2015,

Major objective: It is our aim to develop a lipid based diet that is able to delay or prevent onset of Alzheimer’s disease and related diseases and has a stabilizing effect on cognitive performance in aging. Multiple lines of evidence suggest that there is a large overlap between risk factor of these three diseases. Importantly, there is equally strong evidence that prevention and treatment of the ...
Voir le projet

 19

 TERMINÉ 

Alcohol Measures for Public Health Research Alliance (AMPHORA) (AMPHORA)

Date du début: 1 janv. 2009, Date de fin: 31 déc. 2012,

"AMPHORA is a Europe wide project involving researches and research institutions from 14 European countries, and counterparts and organizations from all 27 Member States, that will provide new scientific evidence for the best public health measures to reduce the harm done by alcohol through addressing social and cultural determinants, marketing and advertising, taxes and pricing, availability and ...
Voir le projet

 33

 TERMINÉ 

Genomic variations underlying common behavior diseases and cognition trait in human populations (ADAMS)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2012,

"The subject of the proposal is the search and analysis of genomic variations underlying Alzheimer's disease (AD), alcoholism and schizophrenia – wide-spread diseases in human populations. Schizophrenia and alcoholism are common forms of behavior pathology and disability in adult life. AD is a most common form of dementia in human populations. Though the genomic variations presumably associated wi ...
Voir le projet

 12

 TERMINÉ 

Serotonin and GABA-B receptors in anxiety : from developmental risk factors to treatment (DEVANX)

Date du début: 1 févr. 2008, Date de fin: 31 juil. 2012,

"GABAergic and serotoninergic systems are key players in the control of anxiety states but the precise bases for their action has remained elusive. New findings, brought about by members of this consortium, are radically changing our views on the neurobiological action of these two transmitters and will be the focus of the present proposal. The first original dimension is the discovery of a develo ...
Voir le projet

 8

 TERMINÉ 

Intelligent and Efficient Travel Management for European Cities (In-Time)

Date du début: 1 avr. 2009, Date de fin: 31 mars 2012,

In-Time (Intelligent and Efficient Travel management for European Cities) focuses on Multimodal Real Time Traffic and Travel Information (RTTI) services with the goal to reduce drastically energy consumption in urban areas across the different modes of transport by changing the mobility behaviour (modal shift) of the single traveller.In-Time provides mainly 3 services:Business-to-business services ...
Voir le projet

 22

 TERMINÉ 

Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders (SchizDX)

Date du début: 1 oct. 2008, Date de fin: 31 mars 2012,

Schizophrenia and bipolar affective disorder are a major burden to affected individuals and their families and to society at large. These two severe mental illnesses affect at least 2% of the population worldwide, and whilst 50% of sufferers do not receive adequate treatment, they cost hundreds of billions in healthcare provision, treatments and lost earnings. The current diagnosis of schizophreni ...
Voir le projet

 9